AOD-9604

Modified human-growth-hormone fragment 176–191 · investigational metabolic research peptide

≥ 99.0% · target, verify batch COACAS 221231-10-3RUO

Research statusInvestigational history; obesity program discontinued after a negative Phase 2b result; RUO only

Supplied formLinear 16-residue peptide with an added N-terminal tyrosine and an intramolecular disulfide bond

Lead time10–18 days

AOD-9604 — Lot-specific lyophilized research peptide; confirm colour and cake condition on the released-batch COA

AOD-9604 — Lot-specific lyophilized research peptide; confirm colour and cake condition on the released-batch COA · Representative packaging image · verify the ordered lot

Representative packaging image · verify the ordered lot

Decision summary

Key benefits

Research applications include adipocyte lipolysis and lipogenesis models, β3-adrenergic-receptor-related signaling, comparison with full-length hGH or hGH fragments, peptide degradation and disulfide-stability studies, and preclinical cartilage or tissue-remodeling models
Reported animal or historical trial observations are not approved therapeutic benefits and do not establish a current product claim.

Published research context is presented for literature orientation only. It is not a dosing, treatment or human-use instruction.

Qualification data

Specifications to confirm against the released lot

CAS: 221231-10-3
Formula: C₇₈H₁₂₃N₂₃O₂₃S₂
Molecular weight: 1,815.1 Da
Appearance: Lot-specific lyophilized research peptide; confirm colour and cake condition on the released-batch COA
Purity: ≥ 99.0% · target, verify batch COA
Storage: Follow the released lot COA, SDS and formulation-specific stability statement. Temperature, light protection, shipping range, buffer, concentration, container and any post-reconstitution hold time require stability-indicating evidence for the exact supplied form. Do not infer storage or in-use dating from another supplier, a trial formulation or generic peptide advice.
MOQ: On request
Lead time: 10–18 days

PubChem CID 71300630

Qualification matrix

Identity, purity and content are separate release questions.

Identity

Confirm the stated molecule and supplied form. Start with the matching batch COA; request sequence-level evidence only when the buyer's written procedure requires it and availability or a separate scope has been agreed.

Purity

Review RP-HPLC method conditions, wavelength, integration and related-peak handling. A percentage without the method is not enough.

Content

Net peptide content is not the same as gross lyophilized powder weight. Ask which assay supports the stated amount and whether water/counter-ion is addressed.

Stability

Define long-term storage and transit exposure separately. Cold-chain can be quoted when the buyer’s risk assessment requires it and adds cost.

Research context

What researchers study about AOD-9604

AOD-9604 is a modified 16-residue peptide derived from the C-terminal region of human growth hormone, commonly described as hGH residues 176–191 with an added N-terminal tyrosine. It was developed as an obesity candidate and studied in several human trials. The pivotal 24-week Phase 2b OPTIONS trial did not meet its primary weight-loss endpoint, and the sponsor terminated that indication in 2007. AOD-9604 is not an FDA-approved finished drug. On 4 December 2024, the FDA Pharmacy Compounding Advisory Committee recommendation weighed against adding the free base or acetate to the 503A Bulks List. The 2026 WADA Prohibited List is in force for athletes subject to anti-doping rules. This catalogue material is RUO only.

Laboratory topics include adipocyte metabolism, β3-adrenergic-receptor biology, comparison of hGH-derived fragments, peptide degradation, disulfide integrity and preclinical cartilage or tissue-remodeling models
No approved obesity, joint, wellness or other clinical indication is established.

Mechanism context

The question the literature is testing

Preclinical studies report acute metabolic effects that may not require β3-adrenergic receptors and longer-term changes associated with β3-adrenergic-receptor expression. Other publications describe a profile distinct from full-length hGH. These mechanisms remain model-dependent: they do not prove clinically meaningful fat loss, joint repair, absence of GH-receptor signaling or lack of IGF-1 and glucose effects for every formulation or lot. Direct receptor, pathway and orthogonal comparator controls are required.

Evidence map

Research routes and exposure context

Evidence tierHuman clinical research

Research areaGrowth-hormone axis research

Routes reported in sources

SubcutaneousIntravenousOral

Dose / exposure contextProtocol-specific; verify the cited primary source

Routes and exposure contexts summarize cited studies or approved finished-product labels. They are not instructions for administering this RUO material; no customer dose is provided.

Evidence boundaries

Compatibility, limitations and decision context

Not an approved finished medicine and not for human or veterinary use
Historical trial data apply only to the studied formulations, routes, populations and durations and do not establish the safety of an RUO supplier lot or community injection practice
FDA advisory materials identified characterization, aggregation, peptide-related impurity and immunogenicity concerns and recommended against 503A-list inclusion at the 4 December 2024 meeting
WADA prohibits AOD-9604 for covered athletes
Laboratory work should follow the lot SDS and institutional controls; this catalogue provides no administration, pregnancy, monitoring or adverse-event advice.

Interactions reported in the literature

No controlled evidence establishes product-specific compatibility or synergy with hyaluronic acid, GLP-1/GIP medicines, BPC-157, CJC-1295, ipamorelin, insulin or other materials in humans
A rabbit osteoarthritis experiment is animal-model context only
Experimental co-use requires a protocol-specific rationale, physical and chemical compatibility data and direct safety and pathway controls.

Literature context is not a supplier release result or human-use instruction. Follow your institution's approved laboratory risk assessment.

Factory batch documentation

AOD-9604 factory batch COAs

AOD-9604 2 mg Factory batch COA protected preview

AOD-96042 mg · WHJLP-AOD2-260316-C

AOD-9604 5 mg Factory batch COA protected preview

AOD-96045 mg · WHJLP-AOD5-260316-C

AOD-9604 10 mg Factory batch COA protected preview

AOD-960410 mg · WHJLP-AOD10-260316-C

Representative records, refreshed periodically

Published COAs show representative factory batches and may not be the latest available. For a current quote or shipment, our sales team can confirm the applicable lot and provide its COA.

Independent testing, arranged on request

Third-party reports are not routinely published. If independent verification is required, we can agree the laboratory, method, acceptance criteria and remedy before testing. If the agreed specification is not met, an appropriate resolution—including a refund where applicable—can be discussed under the agreed terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Help reviewing your COA

Need help reading a factory COA or third-party report? Our sales team can clarify test items, specifications and how the results relate to the lot under discussion.

Ask for the current packet, not a generic certificate

Define the complete sequence, N-terminal modification, termini, intramolecular disulfide connectivity, salt or counterion and formulation
Require lot traceability, theoretical and high-resolution observed intact mass, sequence-level evidence where appropriate, a stability-indicating chromatographic purity and impurity profile, quantitative peptide content, water, residual solvents, aggregation assessment where relevant and lot-specific stability
Sterility, endotoxin and bioburden are separate released-lot claims
Appearance, dissolution or HPLC area percentage alone cannot establish content, disulfide integrity, clinical suitability or safety.

Released-batch COARP-HPLC result and method contextIdentity result appropriate to the moleculeWater / counter-ion context where relevantSDS and handling statementAdditional testing scoped on request

Available fills

Quote the fill and pack configuration you need

Reference SKUFillBase pack

AOD-02MG2 mg10 vials

AOD-05MG5 mg10 vials

AOD-10MG10 mg10 vials

Handling

Storage in the lab and temperature during transit are different decisions

Follow the released lot COA, SDS and formulation-specific stability statement. Temperature, light protection, shipping range, buffer, concentration, container and any post-reconstitution hold time require stability-indicating evidence for the exact supplied form. Do not infer storage or in-use dating from another supplier, a trial formulation or generic peptide advice.

State destination, season, acceptable transit exposure and whether your protocol requires insulated or cold-chain service. Additional temperature-control cost is quoted explicitly.

Buyer FAQ

Terms to settle before the purchase order

Can a buyer arrange third-party testing?+

Yes. Testing must be performed by a mutually accepted, established specialist laboratory. Fee allocation, specification, sampling, method and acceptance rule must be agreed before testing; if an agreed independent result shows nonconformance, the remedy follows the signed order terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Does HPLC purity prove peptide content?+

No. Chromatographic purity describes the relative peak profile under a stated method. Identity, water, counter-ion, residual solvents and assay/content may require separate methods.

Is cold-chain shipping always required?+

Not always. Heat can accelerate degradation, especially during summer and long transit. Cold-chain reduces exposure but raises cost. State the destination and stability risk so the right service can be quoted.

How are payment terms handled?+

Available methods and milestones depend on order value, destination and project type. The pro forma invoice should state currency, bank details, fees, payment milestones and the release condition.

Why must the testing laboratory understand peptide chemistry?+

Free-base and salt forms, hydrophilic and hydrophobic sequences, aggregation and adsorption can change sample preparation and method suitability. Use a laboratory experienced with the molecule class.

External qualification references

WHO good storage and distribution practices IATA Temperature Control Regulations ISO/IEC 17025 laboratory competence 21 CFR 211.84 component testing and supplier COA controls

These are buyer-qualification references, not claims that this RUO material is regulated, certified or released under those frameworks. Applicability depends on the buyer's workflow and jurisdiction.

Selected sources

Literature behind the research context

Identity: PubChem CID 71300630, formula C₇₈H₁₂₃N₂₃O₂₃S₂ and molecular weight approximately 1815.1 Da. Clinical-development context: FDA Pharmacy Compounding Advisory Committee briefing materials for 4 December 2024 summarize the human program and negative 24-week Phase 2b OPTIONS result; the committee recommendation weighed against adding AOD-9604 free base or acetate to the 503A Bulks List. Stier et al. 2013 provides pooled tolerability context for studied trials but does not validate current community routes or products. Moré and Kenley 2014 reports animal/in-vitro metabolism data. Wu et al. 2015, PMID 26275694, is a rabbit osteoarthritis study, not a human trial. The 2026 WADA Prohibited List provides current anti-doping context. Consumer claims of TGA-approved iTRAM use were not accepted without a primary regulatory source.

01
Metabolic Studies of a Synthetic Lipolytic Domain (AOD9604) of Human Growth Hormone
Hormone Research (Karger) · 2000 · peer-reviewed original research (preclinical, rodent)
Open source
02
The Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism Following Chronic Treatment in Obese Mice and β3-AR Knock-Out Mice
Endocrinology (Oxford Academic / Endocrine Society) · 2001 · peer-reviewed original research (preclinical, mechanism)
Open source
03
Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model
Annals of Clinical & Laboratory Science · 2015 · peer-reviewed original research (preclinical, rabbit model)
Open source
04
Safety and Metabolism of AOD9604, a Novel Nutraceutical Ingredient for Improved Metabolic Health
Journal of Endocrinology and Metabolism · 2014 · peer-reviewed review/summary of nonclinical toxicology and pharmacokinetic data
Open source
05
Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans
Journal of Endocrinology and Metabolism · 2013 · peer-reviewed review/pooled summary of clinical safety data
Open source
06
AOD-9604 Does Not Influence the WADA hGH Isoform Immunoassay
Drug Testing and Analysis (Wiley) · 2013 · peer-reviewed original research (analytical/anti-doping)
Open source
07
Obesity Drug Codenamed AOD9604 Highly Successful in Trials
News-Medical.net (trade/science news, sourced from company press release) · 2004 · company press release republished by trade news outlet
Open source
08
Pharmacy Compounding Advisory Committee (PCAC) Briefing Document — AOD-9604 (Free Base) and AOD-9604 (Acetate) Evaluation for 503A Bulk Drug Substances List
U.S. Food and Drug Administration · 2024 · regulatory document (FDA advisory committee briefing/evaluation)
Open source

Product FAQ

Questions buyers ask about AOD-9604

What does AOD-9604's clinical-development history establish?+

AOD-9604 entered an obesity-development program and was studied in several human trials, but the pivotal 24-week Phase 2b OPTIONS study did not meet its primary weight-loss endpoint and the sponsor ended that indication in 2007. This history provides safety and pharmacology context for the studied formulations and routes; it does not make a current RUO batch an approved medicine or establish a subcutaneous, joint, weight-loss or wellness use.

Is AOD-9604 simply a smaller form of growth hormone?+

It is a modified peptide derived from the C-terminal region of human growth hormone, but published models describe a pharmacology distinct from full-length hGH. Statements about lipolysis, β3-adrenergic-receptor expression, lack of GH-receptor activity or absence of IGF-1 effects are model- and formulation-dependent; they are not proof of human efficacy or a broadly safer profile. Mechanistic experiments should use direct receptor, pathway and comparator controls.

What do FDA and WADA references mean for buyers?+

At its 4 December 2024 meeting, the FDA Pharmacy Compounding Advisory Committee recommendation weighed against adding AOD-9604 free base or acetate to the 503A Bulks List; an advisory recommendation is not marketing approval. Separately, WADA prohibits AOD-9604 for athletes subject to its rules. Neither status verifies a supplier lot, so identity, quality and intended-use controls remain separate procurement questions.

AOD-9604

Key benefits

Specifications to confirm against the released lot

Identity, purity and content are separate release questions.

What researchers study about AOD-9604

The question the literature is testing

Research routes and exposure context

Compatibility, limitations and decision context

Interactions reported in the literature

AOD-9604 factory batch COAs

Ask for the current packet, not a generic certificate

Quote the fill and pack configuration you need

Storage in the lab and temperature during transit are different decisions

Terms to settle before the purchase order

Literature behind the research context

Metabolic Studies of a Synthetic Lipolytic Domain (AOD9604) of Human Growth Hormone

The Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism Following Chronic Treatment in Obese Mice and β3-AR Knock-Out Mice

Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model

Safety and Metabolism of AOD9604, a Novel Nutraceutical Ingredient for Improved Metabolic Health

Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans

AOD-9604 Does Not Influence the WADA hGH Isoform Immunoassay

Obesity Drug Codenamed AOD9604 Highly Successful in Trials

Pharmacy Compounding Advisory Committee (PCAC) Briefing Document — AOD-9604 (Free Base) and AOD-9604 (Acetate) Evaluation for 503A Bulk Drug Substances List

Questions buyers ask about AOD-9604

Compare adjacent molecules and documentation needs.

HGH Fragment176191

Sermorelin

Ipamorelin

GHRP-2